1. Medtech Insight
  2. >>Geography
  3. >>Asia

India’s Simmering Device-Pricing Controversy – Many Hues

 
• By Anju Ghangurde

An uneasy calm prevails in the medical devices sector in India following regulatory action to cap stent prices and, more recently, a price data-gathering initiative for certain other products. Is this just the lull before another, more turbulent storm that lies ahead for industry?

Taj Mahal

India's recent regulatory action to rein in the prices of coronary stents seems to have left the medical devices segment nursing some bruises. However, there are fears that more of such action may be brewing for industry.

Part of the apprehension appears stoked by recent diktats, including a note by India’s health ministry to the Medical Council...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

More from Geography

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 
• By Amanda Maxwell

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

EU Life Sciences Strategy Must Address ‘Regulatory Lasagna’

 
• By Amanda Maxwell

MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”